Physician profile
Warner Peng
NPI 1154584704
$21,107.37
in general payments reported to CMS, 2019-2025
71 companies · $4,749 in 2025
The $4,749 reported for 2025 was more than what 81% of Hematology & Oncology providers received nationally (typical 2025 total: $686).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $312 · 2020: $2,064 · 2021: $1,410 · 2022: $3,783 · 2023: $4,191 · 2024: $4,598 · 2025: $4,749.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $13K · Education: $113.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $13,425.38 |
| Education | $112.75 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novartis Pharmaceuticals Corporation | $1,606.26 | 2019-2025 | |
| Incyte Corporation | $1,456.20 | 2019-2025 | Jakafi, Pemazyre, Monjuvi |
| Astrazeneca Pharmaceuticals LP | $1,439.29 | 2020-2025 | Enhertu, Imfinzi, Calquence |
| Janssen Biotech, INC. | $1,415.51 | 2020-2025 | Tecvayli, Talvey, Darzalex |
| Merck Sharp & Dohme LLC | $1,177.66 | 2020-2025 | Keytruda, Lynparza, Welireg |
| Pfizer INC. | $1,131.42 | 2020-2025 | |
| Celgene Corporation | $1,002.10 | 2020-2025 | Reblozyl, Pomalyst, Opdualag |
| Eisai INC. | $791.15 | 2020-2025 | |
| E.R. Squibb & Sons, L.L.C. | $786.92 | 2020-2025 | Opdivo, Opdualag |
| Takeda Pharmaceuticals U.S.A., INC. | $780.40 | 2020-2025 | Iclusig, Fruzaqla, Alunbrig |
| Exelixis INC. | $751.11 | 2019-2025 | Cabometyx |
| Astellas Pharma US INC | $600.67 | 2020-2025 | Xtandi, Xospata, Vyloy |
| Daiichi Sankyo INC. | $537.54 | 2020-2025 | Enhertu, Datroway |
| Karyopharm Therapeutics INC. | $453.09 | 2020-2025 | Xpovio |
| Seagen INC. | $447.84 | 2020-2023 | Tukysa, Adcetris, Tivdak |
Show all 71 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Warner Peng listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.